Clinical Trials Logo

Residual Cancer clinical trials

View clinical trials related to Residual Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT04434040 Active, not recruiting - Breast Cancer Clinical Trials

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Start date: July 2, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: - Sacituzumab govitecan - Atezolizumab